This website is intended for healthcare professionals only.
The European Society of Cardiology Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic states that ‘patients with cardiovascular risk factors and established cardiovascular disease represent a vulnerable population when suffering from COVID-19’. Interventional cardiologists and hospital managers find themselves in the front line of ensuring optimal hospital efficiencies that translate into best clinical care for their patients.
PD Dr. Mariuca Vasa-Nicotera and Maria Zisiopoulou from University Hospital Frankfurt explore their experiences on the benefits of TAVI for their hospital during these unprecedented times.
PD Dr. Mariuca Vasa-Nicotera
Deputy Director of the Cardiology Clinic
University Hospital Frankfurt, Frankfurt, Germany
Clinic Manager and QMB Cardiology Coordinator
University Hospital Frankfurt, Germany
Prof. Anthony Mathur from Barts Health NHS Trust and Sophie Nicholls from Bristol Heart Institute share their experiences with TAVI from different perspectives.
Prof. Anthony Mathur
Barts Health NHS Trust, London, UK
General Manager of Cardiac Services
Bristol Heart Institute, Bristol, UK
Defining the patient population
Optimising organisational efficiencies in the treatment of patients with ssAS
Budget considerations for the use of TAVI
Impact of choice of therapy on patient safety, quality of life and health outcomes
How partnerships might add value, manage risk and enable innovation